![Kerry Wentworth](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kerry Wentworth
General Counsel bei
NUVATION BIO INC.
Vermögen: 253 340 $ am 31.05.2026
Profil
Kerry A. Wentworth is Director at Massachusetts Biotechnology Council since 2019 and Chief Regulatory Officer at Nuvation Bio, Inc. since 2022.
Former roles include Senior Director-Regulatory Affairs at Genelabs Technologies, Inc., Vice President-Clinical, Regulatory & Quality at Agenus, Inc. from 2013 to 2014, Chief Regulatory Officer at Flexion Therapeutics, Inc. from 2017 to 2021, and Head-Regulatory Affairs at Genzyme Corp.
Education includes undergraduate studies at the University of New Hampshire.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 23.06.2026 | 53 000 ( 0,02 % ) | 253 340 $ | 31.05.2026 |
Aktive Positionen von Kerry Wentworth
| Unternehmen | Position | Beginn |
|---|---|---|
| NUVATION BIO INC. | General Counsel | 18.07.2022 |
Massachusetts Biotechnology Council
 Massachusetts Biotechnology Council Miscellaneous Commercial ServicesCommercial Services Operates as an association of biotechnology companies | Direktor/Vorstandsmitglied | 01.04.2019 |
Ehemalige bekannte Positionen von Kerry Wentworth
| Unternehmen | Position | Ende |
|---|---|---|
| FLEXION THERAPEUTICS, INC. | General Counsel | 19.11.2021 |
| AGENUS INC. | Technik-/Wissenschafts-/F&E-Leiter | 10.07.2014 |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | General Counsel | - |
Genelabs Technologies, Inc.
 Genelabs Technologies, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products and performs life science research and development | General Counsel | - |
Ausbildung von Kerry Wentworth
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
61
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Genelabs Technologies, Inc.
Genelabs Technologies, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products and performs life science research and development | Health Technology |
Agenus, Inc.
 Agenus, Inc. BiotechnologyHealth Technology Engages in the development and commercialization of technologies to treat cancers and infectious diseases | Health Technology |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes therapies for the treatment of patients with musculoskeletal conditions | Health Technology |
University of New Hampshire
 University of New Hampshire Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Biotechnology Council
Massachusetts Biotechnology Council Miscellaneous Commercial ServicesCommercial Services Operates as an association of biotechnology companies | Commercial Services |
Nuvation Bio, Inc.
 Nuvation Bio, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops oncology related novel therapeutic candidates | Health Technology |
Wählen Sie MarketScreener 
